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Profiling of cardio-metabolic risk 
factors and medication utilisation among Type 
II diabetes patients in Ghana: a prospective 
cohort study
Eric Adua1, Peter Roberts1, Samuel Asamoah Sakyi2, Francis Agyemang Yeboah2, Albert Dompreh3, 
Kwasi Frimpong1, Enoch Odame Anto1 and Wei Wang1*
Abstract 
Background: Type II diabetes mellitus (T2DM) is complicated by multiple cardio-metabolic risk factors. Controlling 
these factors requires lifestyle modifications alongside utilisation of anti-diabetic medications. Different glucose low-
ering [(biguanides (BIGs), sulfonylureas (SUAs), thiazolidinediones (TNZ)], lipid lowering (statins), and anti-hypertensive 
medicines [angiotensin converting enzyme inhibitors (ACEIs), calcium channel blockers (CCBs), angiotensin II receptor 
blockers (ARBs) and central acting drugs (CADs)] have been approved for controlling hyperglycaemia, dyslipidaemia 
and hypertension respectively. Here, we examined factors that characterise T2DM and explored the response to medi-
cation therapy among T2DM patients.
Methods: This prospective cohort study recruited 241 T2DM patients reporting at a clinic in Ghana, from January 
through to August, 2016. Each patient’s demographic, medications and anthropometric data was obtained while 
information on medication adherence was captured using Morisky adherence scale-8 (MMAS-8). Fasting blood sam-
ples were collected for biochemical analysis.
Results: The mean age of participants was 57.82 years for baseline and six-month follow-up. Physical activity differed 
at baseline and follow up (p < 0.05) but not body mass index (BMI). BIG alone, or in combination with SUA and TNZ 
did not improve glycaemic status at follow up (p > 0.05). Many participants using either ACEI or ARB were able to con-
trol their blood pressures. Among dyslipidaemia patients under statin treatment, there was an improved lipid profile 
at follow-up.
Conclusions: Statin medications are effective for reducing dyslipidaemia in T2DM patients. However, control of 
modifiable risk factors, particularly blood glucose and to a lesser degree blood pressure is suboptimal. Addressing 
these will require concomitant interventions including education on medication adherence and correct dietary plans, 
lifestyle modifications and physical activity.
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Background
Despite substantial efforts, type II diabetes mellitus 
(T2DM) remains a major contributor to the world’s 
morbidity and mortality [1, 2]. In 2014 alone, more 
than 2.2 million people died from the disease and at 
approximately the same time, nearly 415 million adults 
were affected worldwide, representing a prevalence 
rate of ≈8.5% [2, 3]. This prevalence rate is expected to 
translate into 439 million T2DM cases by 2030 [3, 4]. 
Unfortunately, countries with less healthcare resources 
such as those in sub-Saharan Africa (SSA) are among 
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the most affected with some 14.2 million people pres-
ently suffering from the disease [2]. For example, in 
Ghana, T2DM affected more than 266,200 individuals 
at a prevalence rate of 6% in 2015, and it is presently 
ranked among the top 10 causes of all adult deaths [2, 
5].
People with T2DM have an increased risk of develop-
ing many health problems such as cardiovascular dis-
eases [6, 7], amputations [8], depression [9, 10], and 
cognitive impairment [11–14]. Moreover, prolonged 
hyperglycaemia is strongly linked with many microvascu-
lar and, to a lesser extent, macrovascular complications 
and premature mortality [15]. In fact, just a 1% rise in 
glucose level will lead to an 18% increased risk for cardio-
vascular events [16], 37% increased risk for renal diseases 
[11] and 12–14% increased risk for premature mortality 
[11, 15, 16].
Additionally, the majority of T2DM patients are physi-
cally inactive which has led to dyslipidaemia, obesity 
and hypertension [17, 18]. These in turn lead to further 
consequences. Studies have shown that obesity accounts 
for 14% of all adult deaths while hypertension alone is an 
independent risk factor for cognitive decline [19], renal 
dysfunction [20, 21] and ultimately responsible for 45% of 
all deaths. Therefore, given these detrimental outcomes, 
controlling known modifiable factors should be a priority.
It has long been documented that achieving good gly-
caemic levels is pivotal to delaying T2DM complica-
tions. According to the American Diabetes Association 
(ADA), reduction of microvascular and macrovascular 
complications is possible at HbA1c <7% [22]. This could 
be achieved with single, combination or multiple glucose 
lowering medications [23, 24].
Alongside maintaining normal glycaemic levels, ther-
apeutic interventions should be extended to other con-
comitant factors such as dyslipidaemia, hypertension 
and obesity [25, 26]. Different lipid lowering and anti-
hypertensive medicines have been approved for con-
trolling dyslipidaemia and hypertension respectively; 
majority of which are currently available in Ghana 
[5, 26]. Yet, the control of T2DM modifiable factors 
has been suboptimal, partly because studies to create 
awareness of T2DM are generally scarce in this region. 
Moreover, these studies have mainly been cross-sec-
tional providing limited information on association or 
causality. Therefore, in this study, we explored the man-
ifestations and the associated factors that characterise 
T2DM in a longitudinal design. Additionally, this study 
highlights the proportion of T2DM patients that have 
good glycaemic control, blood pressure and lipid levels 
and addresses the factors that contribute to poor man-
agement and control of these modifiable risk factors.
Methods
Study design
This prospective cohort study was conducted at the dia-
betic clinic of the Komfo Anokye Teaching Hospital 
(KATH) from January through to August 2016. In all, 241 
participants with T2DM aged 35–70 years who reported to 
the clinic for review and medications were recruited. The 
study protocol was reviewed by the Committee on Human 
Research, Publication and Ethics (CHRPE), Kwame Nkru-
mah University of Science and Technology (KNUST), 
Kumasi and the Human Research Ethics Committee 
(HREC), Edith Cowan University (ECU), Australia. Written 
informed consent was obtained from each participant.
Inclusion and exclusion criteria
The study included only those who were diagnosed as 
having T2DM, based on the international classification 
of diabetes (ICD 10) criteria. Participants who were tak-
ing insulin injections were assumed to be suffering from 
type I diabetes mellitus and therefore were excluded. 
Additionally, among the original 260 T2DM participants 
recruited for the study, 19 were excluded, mainly because 
of missing clinical data.
Anthropometric and blood pressure measurements
After obtaining demographic data and information on 
the general health status from each participant, infor-
mation of medication adherence was obtained using the 
validated Morisky Adherence Scale-8 (MMAS-8). This 
questionnaire comprises 8 items and responses for item 1 
through 7 are either ‘yes’ or ‘no’ whereas item 8 comprises 
a 5-point Likert scale [27]. Following this, anthropomet-
ric measurements were taken. Weight (kg) and height 
(cm) were measured with a standard stadiometer (SECA, 
Hamburg, Germany). These were used to determine the 
body mass index (BMI), calculated as BMI = weight (kg)/
height (m)2. Waist and hip circumference were measured 
in cm using a tape measure and waist-to-hip ratio (WHR) 
was calculated as WHR =  waist (cm)/hip (cm). Systolic 
blood pressure (SBP) and diastolic blood pressure (DBP) 
were measured using a standard sphygmomanometer 
(Omron HEM711DLX, UK). To assess the level of physi-
cal activity, we asked basic questions such as 1) what is 
the level of physical activity during the last 7 days?, 2) on 
how many days did you walk for at least 10 min at a time 
in your leisure time?
Blood sample collection and biochemical assay
Venous fasting blood samples were collected from 
each participant into tubes containing EDTA (ethylene 
diamine tetraacetic acid), fluoride oxalate and gel sepa-
rator. Fasting plasma glucose (FPG) in fluoride tubes 
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and glycated haemoglobin (HbA1c) in EDTA tubes were 
measured on an automated chemistry analyser (Roche 
Diagnostics, COBAS INTEGRA 400 Plus, USA). Simi-
larly, serum total cholesterol (TC), high density lipo-
protein cholesterol (HDL-c), low density lipoprotein 
cholesterol (LDL-c), and triglycerides (TG) were meas-
ured on the automated chemistry analyser (Roche Diag-
nostics, COBAS INTEGRA 400 Plus, USA). Non-HDL 
was calculated as Non-HDL  =  total cholesterol-HDL. 
Coronary risk ratio and very low density lipoprotein 
(VLDL) cholesterol were calculated on the automated 
chemistry analyser. Various medications utilised by the 
T2DM patients at the clinic are shown in Fig. 1.
Definition of terms
High plasma glucose; FBG >7  mmol/L, HbA1c >7.2% 
[28].
Normal BP; 140/90  mmHg, high SBP >140  mmHg, 
high DBP >90 mmHg [29].
Dyslipidaemia: waist circumference ≥102  cm (males), 
≥88  cm (females), WHR >90 (men) and 0.85 (female). 
High TG ≥1.7 mmol/l, HDL-C <1.0 (male), 1.03 (female), 
high LDL-C ≥2.59  mmol/l, high total cholesterol 
≥5.18 mmol/l, high non-HDL ≥3.37 mmol/l [30].
Statistical analysis
Normality distribution was checked by the Shapiro–Wilk 
test. All continuous data was recorded as mean ± stand-
ard deviation and as frequency (percentages) for categori-
cal variables. Between group comparisons for continuous 
variables were performed using student t-tests, and inter-
group comparisons of categorical variables were per-
formed using Chi square tests. Association between 
categorical variables and FBG or HbA1c were performed 
using logistic regression models and odds ratios (ORs) 
at 95% confidence intervals (95% CI) were recorded. All 
statistical analyses were performed using the Statistical 
Package for Social Sciences (SPSS), version 22. A p < 0.05 
was considered significant.
Results
Among the study population, the male to female ratio 
was 99/142 at baseline and 66/94 at follow up respec-
tively. BMI and WHR of participants did not significantly 
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differ from baseline to follow up [i.e. (p  =  0.172) and 
(p  =  0.276) respectively]. However, there was a signifi-
cant difference in levels of physical activity from baseline 
to 6-month follow up (p = 0.0001) (Table 1).
The majority of the study participants were aged 
51–60  years [81 (33.6%) vs 55 (34.4%)] while the low-
est age range was 31–40  years [14 (5.8%) vs 10 (6.3%)] 
(Table 2). The severity and mean levels of the measured 
parameters were not significantly different from base-
line to follow-up; [SBP (p = 0.474 and p = 0.600), DBP 
(p = 0.382 and p = 0.620), FBG (p = 0.364 and p = 0.940), 
TC (p  =  0.328 and p  =  0.160), non-HDL (p  =  0.270 
and p =  0.250) and LDL-c (p =  0.092 and p =  0.430)]. 
However, there was a difference in the severity and 
mean levels of HbA1c [(p = 0.004 and p = 0.0001)], TG 
[(p = 0.006 and p = 0.0001)] and HDL-c [(p < 0.0001 and 
p = 0.0001)] from baseline to follow up (Table 2).
After adjusting for age and medication use, high BMI, 
SBP, DBP, TC, TG, HDL, non-HDL-c, and LDL-c status 
were not significant independent risk factors for high 
FBG in both baseline and follow up groups (p  >  0.05) 
(Table  3). Similarly, in the logistic regression model, 
increased SBP, DBP, TC and non-HDL were slightly 
associated with high HbA1c levels at both baseline and 
follow up but not significantly (p > 0.05) (Table 4). 
From baseline to follow up, FBG levels increased by 
25.0% when (BIG) was administered alone. In a combi-
nation therapy with either SUA or TNZ, there was only 
a decrease in FBG levels by 1% (p  =  0.9924) and 1.6% 
(p = 0.1098) respectively. However, FBG levels decreased 
by 15.8% when all three medications; BIG, SUA and 
TNZ were administered (p  =  0.216). Meanwhile, levels 
of HbA1c were increased by 29.6% after BIG treatment 
alone (p = 0.0094), increased by 19.2% and 16.7% when 
BIG was combined with SUA (p  =  0.0175) and TNZ 
(p  =  0.0903) respectively. However, a multiple therapy 
of BIG, SUA and TNZ resulted in only a 1.3% increase of 
HbA1c levels (p = 0.8308) (Table 5).
There was a mean percentage decrease effect in lev-
els of HDL-c (p < 0.0001), TG (p = 0.0259) and VLDL-c 
(p = 0.0237) by 22.8%, 18.4% and 17.3% respectively, after 
atorvastatin treatment alone. Conversely, there was an 
increased effect in levels of TC (p = 0.743) by 1.7%, non-
HDL-c (p = 0.075) by 14.5%, LDL-c (p = 0.022) by 21.5% 
and CR (p = 0.955) by 0.5% after atorvastatin treatment 
(Table 6).
Table 1 Socio-demographic characteristics of study participants: Baseline and follow up
Values are presented as frequency (percentage); mean ± SD
t t-test value
Variable Total Baseline (n = 240) Follow up (n = 160) X2, df p value
Age (years) 57.80 ± 10.63 57.82 ± 10.88 57.79 ± 10.39 0.370t 0.981
Male:female ratio 165/236 99/142 66/94
BMI (Kg/m2) 26.80 ± 9.44 26.13 ± 5.11 27.47 ± 13.78 1.367t 0.172
WHR 0.93 ± 0.05 0.93 ± 0.06 0.92 ± 0.05 1.090t 0.276
Marital status 17.5, 3 0.002
 Married 269 (67.1) 164 (68.0) 105 (65.6)
 Never married 6 (1.5) 4 (1.7) 2 (1.3)
 Divorced 41 (10.2) 25 (10.4) 16 (10.0)
 Widowed 85 (21.2) 48 (19.9) 37 (23.1)
Education 3.01, 4 0.55
 Tertiary 58 (14.5) 36 (14.9) 22 (13.8)
 Senior high school 104 (25.9) 57 (23.7) 47 (29.4)
 Junior high school 133 (33.2) 78 (32.4) 55 (34.4)
 Lower primary 43 (10.7) 28 (11.6) 15 (9.4)
 No formal education 63 (15.7) 42 (17.4) 21 (13.1)
Occupation 39.65, 3 0.0001
 Employed 229 (57.1) 133 (55.2) 96 (60.0)
 Retired 85 (21.2) 35 (14.5) 50 (31.1)
 Unemployed 65 (16.2) 51 (21.1) 14 (8.8)
 Informal employment 22 (5.5) 21 (9.0) 1 (1)
Physical activity 25.22, 1 0.0001
 Primarily sedentary 101 (25.2) 79 (32.8) 22 (13.8)
 Moderate activity 300 (74.6) 162 (67.2) 138 (85.5)
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Table 2 Distribution of clinical characteristics among study participants
Variables Total Baseline (n = 241) Follow-up (n = 160) X2, df p value
Age 0.909, 4 1.000
 31–40 24 (6.0) 14 (5.8) 10 (6.3)
 41–50 76 (19.0) 49 (20.3) 27 (16.9)
 51–60 136 (33.9) 81 (33.6) 55 (34.4)
 61–70 118 (29.4) 68 (28.2) 50 (31.3)
 71–80 47 (11.7) 29 (12.0) 18 (11.3)
BMI 3.386, 3 0.336
 Underweight 11 (2.8) 9 (3.80) 2 (1.30)
 Normal weight 175 (43.9) 170 (44.6) 68 (42.8)
 Overweight 132 (33.10) 80 (33.3) 52 (32.7)
 Obese 81 (20.3) 44 (18.3) 37 (23.3)
SBP 0.028, 1 0.474
 Normal 121 (55.1) 132 (54.8) 89 (55.6)
 High 180 (44.9) 109 (45.2) 71 (44.4)
DBP 0.178, 1 0.382
 Normal 298 (74.5) 177 (73.8) 121 (75.6)
 High 102 (25.5) 63 (26.3) 39 (24.4)
HbA1c 7.280, 1 0.004
 Normal 104 (26.0) 74 (30.8) 30 (18.8)
 High 296 (74.0) 166 (69.2) 130 (81.3)
FPG 0.202, 1 0.364
 Normal 160 (39.9) 94 (39.0) 66 (41.3)
 High 241 (60.1) 147 (61.0) 94 (58.8)
TG 6.679, 1 0.006
 Good 343 (86.2) 199 (82.6) 144 (91.7)
 High 55 (13.8) 42 (17.4) 13 (8.3)
TC 0.308, 1 0.328
 Good 259 (65.2) 154 (64.2) 105 (66.9)
 High 138 (34.8) 86 (35.8) 52 (33.1)
HDL 94.80, 1 <0.0001
 Good 235 (59.0) 189 (78.4) 46 (29.3)
 Low 163 (41.0) 52 (21.6) 111 (70.7)
NonHDL 0.474, 1 0.270
 Normal 188 (47.4) 117 (48.8) 71 (45.2)
 High 209 (52.6) 123 (51.3) 86 (54.8)
LDL 2.040, 1 0.092
 Good 164 (41.3) 106 (44.2) 58 (36.9)
 High 233 (58.7) 134 (55.8) 99 (63.1)
SBP (mmHg) 140.06 ± 24.09 139.41 ± 24.31 140.71 ± 23.88 0.525t 0.600
DBP (mmHg) 81.96 ± 13.18 81.63 ± 13.71 82.28 ± 12.65 0.484t 0.620
FBS (mmol/l) 18.32 ± 4.31 9.18 ± 4.42 9.14 ± 4.20 0.082t 0.940
HbA1c (mmol/l) 8.79 ± 2.49 8.27 ± 2.10 9.32 ± 2.88 4.201t 0.0001
TC (mmol/l) 4.63 ± 1.27 4.73 ± 1.27 4.54 ± 1.27 1.406t 0.160
TG (mmol/l) 1.17 ± 0.56 1.27 ± 0.57 1.07 ± 0.56 3.520t 0.0001
HDL-c (mmol/l) 1.19 ± 1.19 1.35 ± 1.35 1.03 ± 1.03 9.960t 0.0001
Non-HDL-c (mmol/l) 3.44 ± 1.22 3.37 ± 1.24 3.52 ± 1.20 1.142t 0.250
LDL-c (mmol/l) 2.91 ± 0.57 2.79 ± 1.16 3.03 ± 1.13 2.029t 0.430
Coronary risk 5.00 ± 2.7 4.97 ± 1.52 5.04 ± 3.88 0.232t 0.820
VLDL-c (mmol/l) 0.54 ± 0.33 0.58 ± 0.26 0.51 ± 0.41 1.965t 0.500
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For non-hypertensive T2DM participants, there 
was no significant change in SBP and DBP from base-
line to follow up (Table 7). SBP levels were reduced by 
0.1% after CCB +  ACEI treatment (p =  0.969). Levels 
of both SBP and DBP were reduced by 1.9% (p = 0.644) 
and 5.8% (p  =  0.128) respectively after ACEI treat-
ment alone and decreased by 1.0% (p = 0.835) and 0.1% 
(p  =  0.912) respectively after CCB  +  ARB combina-
tion therapies. However, levels of both SBP and DBP 
increased by 3.0% (p  =  0.683) and 0.4% (p  =  0.942) 
respectively after CCB treatment alone and increased 
by 17.3% (p = 0.061) and 11.3% (p = 0.086) respectively 
after CAD treatment alone, while a combination ther-
apy of CCB + ACEI increased DBP by 1.9% (p = 0.666) 
(Table 7).
Discussion
The prevalence of T2DM has increased tremendously in 
the past few decades among different countries world-
wide [2, 3, 31–34]. SSA remains one of the most affected 
regions due to rapid urbanisation and increased adoption 
of a westernised diet with less physical activity [5, 30–34].
In this hospital-based study, we examined the major 
factors that characterise T2DM and how these factors 
influence anti-diabetes medication response. As reported 
by Danquah et al. [5], the majority of T2DM patients in 
urban Ghana are middle aged, of low socio-economic sta-
tus and their lifestyle is primarily sedentary [5]. Moreo-
ver, our findings on clinical parameters such as SBP, DBP, 
HDL-c, LDL-c, TG, TC and FBG are similar to those 
reported in their study [5].
Table 3 Association between metabolic risk factors and FBG levels at baseline and follow up
Logistic regression model, adjusted for age and medication. 1.0#: reference point for odds ratio
X2, df Chi square value, degrees of freedom, aOR adjusted odds ratio, CI confidence interval
Variables FBG (baseline) X2, df (p value) p value FBG (follow up) X2, df (p value) p value
High (n = 147) Normal (n = 94) aOR (95% CI) High (n = 94) Normal (n = 66) aOR (95% CI)
Gender 1.38, 1 (0.239) 3.55, 1 (0.06)
 Male 56 (38.1) 43 (45.7) 1.0# 33 (35.1) 33 (50.0) 1.0#
 Female 91 (61.9) 51 (54.3) 1.37 (0.81–2.32) 0.283 61 (64.9) 33 (50.0) 1.85 (0.97–3.51) 0.073
BMI 2.18, 3 (0.537) 1.77, 3 (0.622)
 Underweight 6 (4.1) 3 (3.2) 1.05 (0.25–4.47) 1.000 2 (2.1) 1 (1.5) 1.40 (0.12–16.21) 1.000
 Normal 70 (47.9) 37 (39.4) 1.0# 40 (42.6) 28 (43.1) 1.0#
 Overweight 46 (31.5) 34 (36.2) 0.72 (0.39–1.29) 0.289 29 (30.9) 23 (35.4) 0.88 (0.43–1.83) 0.852
 Obese 24 (16.4) 20 (21.3) 0.63 (0.31–1.30) 0.268 23 (24.5) 14 (21.5) 1.15 (0.51–2.62) 0.836
SBP 0.87, 1 (0.351) 1.13, 1(0.288)
 Normal 77 (52.4) 55 (58.5) 1.0# 49 (52.1) 40 (60.6) 1.0#
 High 70 (47.6) 39 (41.5) 1.28 (0.76–2.16) 0.357 45 (47.9) 26 (39.4) 1.41 (0.75–2.68) 0.333
DBP 0.02, 1 (0.901) 2.34, 1(0.126)
 Normal 108 (73.5) 69 (74.2) 1.0# 67 (73.1) 54 (81.8) 1.0#
 High 39 (26.5) 24 (25.8) 1.04 (0.57–1.88) 1.000 27 (28.7) 12 (18.2) 1.81 (0.84–3.91) 0.139
TC 0.22, 1 (0.642) 0.09, 1 (0.764)
 Good 92 (63.0) 62 (66.0) 1.0# 62 (66.0) 43 (68.3) 1.0#
 High 54 (37.0) 32 (34.0) 1.14 (0.67–1.96) 0.681 32 (34.0) 20 (31.7) 1.11 (0.56–2.19) 0.863
TG 0.23, 1(0.630) 0.52,1 (0.472)
 Good 120 (81.6) 79 (84.0) 1.0# 85 (90.4) 59 (93.7) 1.0#
 High 27 (18.4) 15 (16.0) 1.19 (0.59–2.37) 0.729 9 (9.6) 4 (6.3) 1.56 (0.46–5.31) 0.565
HDL-c 0.01, 1(0.928) 0.83,1 (0.363)
 Good 115 (78.2) 74 (78.7) 1.0# 25 (26.6) 21 (33.3) 1.0#
 Low 32 (21.8) 20 (21.30) 1.03(0.55–1.93) 1.000 69 (73.4) 42 (66.7) 1.38 (0.69–2.77) 0.377
Non-HDL 0.05, 1 (0.827) 0.24,1 (0.621)
 Normal 72 (49.3) 45 (47.5) 1.0# 41 (43.6) 30 (47.6) 1.0#
 High 74 (50.7) 49 (52.1) 0.94 (0.56–1.59) 0.895 53 (56.4) 33 (52.4) 1.18 (0.62–2.23) 0.628
LDL-c 0.88, 1 (0.349) 0.84,1 (0.358)
 Good 68 (46.6) 38 (40.4) 1.0# 32 (34.0) 26 (41.3) 1.0#
 High 78 (53.4) 56 (59.6) 0.78 (0.46–1.32) 0.355 62 (66.0) 37 (58.7) 1.36 (0.71–2.63) 0.401
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Table 4 Association between metabolic risk factors and HbA1c levels at baseline and follow up
Logistic regression model, adjusted for age and medication. 1.0#: reference point for odds ratio
X2, df Chi square value, degrees of freedom, aOR adjusted odds ratio, CI confidence interval
Variables HbA1c (baseline) X2, df (p value) p value HbA1c (follow-up) X2, df (p value) p value
Poor (n = 167) Good (n = 74) aOR (95% CI) Poor (n = 130) Good (n = 30) aOR (95% CI)
Gender 0.18, 1 (0.675) 0.96, 1 (0.328)
 Male 67 (40.4) 32 (43.2) 1.0# 56 (43.1) 10 (33.3) 1.0#
 Female 99 (59.6) 42 (56.8) 1.13 (0.65–1.96) 0.673 74 (56.9) 20 (66.7) 0.66 (0.29–1.52) 0.413
BMI 1.35, 3 (0.718) 4.38, 3 (0.224)
 Underweight 5 (3.0) 4 (5.4) 0.49 (0.12–1.94) 0.445 2 (1.6) 0 (0.0)
 Normal 77 (46.7) 30 (40.5) 1.0# 56 (43.4) 12 (40.0) 1.0#
 Overweight 53 (32.1) 26 (35.1) 0.79 (0.42–1.49) 0.519 45 (34.90 7 (23.3) 1.38 (0.50–3.78) 0.619
 Obese 30 (18.2) 14 (18.9) 0.83 (0.39–1.79) 0.695 26 (20.2) 11 (36.7) 0.50 (0.19–1.29) 0.216
SBP 2.22,1 (0.136) 0.47, 1(0.491)
 Normal 86 (51.8) 46 (62.2) 1.0# 74 (56.9) 15 (50.0) 1.0#
 High SBP 80 (48.2) 28 (37.8) 1.53 (0.87–2.68) 0.161 56 (43.1) 15 (50.0) 0.76 (0.34–1.68) 0.544
DBP 0.16, 1 (0.692) 0.022, 1 (0.883)
 Normal 121 (72.9) 55 (75.3) 1.0# 98 (75.4) 23 (76.7) 1.0#
 High DBP 45 (27.1) 18 (24.7) 1.14 (0.60–2.14) 0.752 32 (24.6) 7 (23.3) 1.07 (0.42–2.73) 1.000
TC 2.42, 1 (0.12) 0.49, 1 (0.483)
 Good 101 (61.2) 53 (71.6) 1.0# 84 (65.6) 21 (72.4) 1.0#
 High 64 (38.8) 21 (28.4) 1.60 (0.88–2.89) 0.144 44 (34.4) 8 (27.6) 1.38 (0.56–3.36) 0.522
TG 0.00, 1 (0.985) 1.42, 1 (0.233)
 Good 137 (82.5) 61 (82.4) 1.0# 119 (93.0) 25 (86.2) 1.0#
 High 29 (17.5) 13 (17.6) 0.99 (0.48–2.04) 1.000 9 (7.0) 4 (13.8) 0.47 (0.14–1.68) 0.262
HDL-c 0.11, 1 (0.743) 0.46, 1 (0.499)
 Good 132 (79.0) 57 (77.0) 1.0# 39 (30.5) 7 (24.1) 1.0#
 Low 35 (21.0) 17 (23.0) 0.90 (0.46–1.73) 0.737 89 (69.5) 22 (75.9) 0.73 (0.29–1.84) 0.652
Non-HDL 0.25, 1 (0.620) 0.002, 1 (0.962)
 Normal 79 (47.9) 38 (51.4) 1.0# 58 (45.3) 13 (44.8) 1.0#
 High 86 (52.1) 36 (48.6) 1.15 (0.66–1.99) 0.675 70 (54.7) 16 (55.2) 0.98 (0.44–2.21) 1.000
LDL-c 0.05,1 (0.817) 0.53,1 (0.465)
 Good 74 (44.8) 32 (43.2) 1.0# 49 (38.3) 9 (31.0) 1.0#
 High 91 (55.2) 42 (56.8) 0.94 (0.54–1.630 0.888 79 (61.7) 20 (69.0) 0.73 (0.31–1.72) 0.528
Table 5 Utilisation of glucose lowering medications among T2DM patients
BIG Biguanide, SUA Sulfonylurea, TNZ Thiazolidinedione
p < 0.05 is considered significant
Baseline Follow up Mean difference (95% CI) p value % effect
Treatment
 FBG (mmol/l)
  BIG only 8.02 ± 0.65 10.08 ± 1.12 2.05 (−1.25 to 5.36) 0.2162 25.00
  BIG + SUA 8.45 ± 0.49 8.441 ± 0.82 −0.01 (−1.83 to 1.82) 0.9924 −0.10
  BIG + TNZ 9.63 ± 0.59 11.88 ± 1.47 2.25 (−0.52 to 5.02) 0.1098 23.40
  BIG + SUA + TNZ 9.921 ± 0.66 8.36 ± 1.04 −1.57 (−4.06 to 0.93) 0.216 −15.80
 HbA1c (%)
  BIG only 7.34 ± 0.28 9.51 ± 1.10 2.17 (0.57 to 3.78) 0.0094 29.60
  BIG + SUA 8.11 ± 0.32 9.67 ± 0.65 1.55 (0.28 to 2.83) 0.0175 19.20
  BIG + TNZ 8.68 ± 0.33 10.12 ± 1.04 1.45 (−0.23 to 3.14) 0.0903 16.70
  BIG + Sul + TNZ 8.46 ± 0.26 8.57 ± 0.47 0.11 (−0.91 to 1.12) 0.8308 1.30
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Table 6 Utilisation of lipid lowering medications among T2DM patients
CI confidence interval
p < 0.05 is considered significant
Variable Baseline Follow up Mean difference (95% CI) p value % difference
TC (mmol/l)
 No statin 5.03 ± 0.12 4.95 ± 0.13 −0.07 (−0.42 to 0.28) 0.6817 1.39
 Atorvastatin 4.06 ± 0.16 4.13 ± 0.16 0.07 (−0.37 to 0.51) 0.7434 1.72
TG (mmol/l)
 No statin 1.32 ± 0.06 1.19 ± 0.06 −0.13 (−0.30 to 0.04) 0.1322 9.85
 Atorvastatin 1.14 ± 0.06 0.93 ± 0.06 −0.21 (−0.39 to −0.03) 0.0259 18.42
HDL-c (mmol/l)
 No statin 1.36 ± 0.03 1.05 ± 0.03 −0.30 (−0.39 to −0.21) <0.0001 22.06
 Atorvastatin 1.36 ± 0.04 1.04 ± 0.04 −0.31 (−0.42 to −0.19) <0.0001 22.79
Non-HDL (mmol/l)
 No statin 3.67 ± 0.11 3.89 ± 0.12 0.23 (−0.09 to 0.55) 0.1617 6.27
 Atorvastatin 2.69 ± 0.15 3.09 ± 0.15 0.39 (−0.04 to 0.81) 0.0754 14.50
LDL-c (mmol/l)
 No statin 3.06 ± 0.11 3.36 ± 0.11 0.30 (−0.01 to 0.60) 0.058 9.80
 Atorvastatin 2.19 ± 0.15 2.68 ± 0.14 0.47 (0.06 to 0.87) 0.022 21.46
CR
 No statin 5.24 ± 0.15 5.57 ± 0.49 0.33 (−0.68 to 1.34) 0.5202 6.29
 Atorvastatin 4.31 ± 0.19 4.32 ± 0.20 0.02 (−0.53 to 0.57) 0.9547 0.46
VLDL-c (mmol/l)
 No statin 0.60 ± 0.03 0.58 ± 0.05 −0.01 (−0.12 to 0.09) 0.8181 1.67
 Atorvastatin 0.52 ± 0.03 0.42 ± 0.03 −0.09 (−0.18 to −0.01) 0.0237 17.3
Table 7 Utilisation of anti-hypertensive medicines among T2DM patients
CCB calcium channel blockers, ACEI angiotensin converting enzyme inhibitors, ARB angiotensin II receptor blockers, CADcentral acting drugs
Anti-hypertensive drugs Baseline Follow up Mean difference (95%CI) p value %effect
SBP (mmHg)
DM only (n = 38) 127.1 ± 4.09 130.5 ± 3.45 3.34 (−7.33 to 14.01) 0.534 2.63
DM + HPT
 CCB (n = 11) 150.2 ± 7.99 154.6 ± 7.21 4.46 (−18.02 to 26.92) 0.683 2.96
 ARB (n = 22) 130.1 ± 3.04 130.0 ± 4.36 0.01 (−10.74 to 10.74) >0.999 0.00
 ACEI (n = 30) 130.4 ± 3.93 128.0 ± 3.59 −2.47 (−13.12 to 8.19) 0.644 −1.90
 CAD (n = 8) 150.6 ± 9.07 176.6 ± 8.33 26.0 (−2.43 to 54.43) 0.061 17.30
 CCB + ARB (n = 24) 153.3 ± 5.74 151.7 ± 4.98 −1.58 (−16.88 to 13.72) 0.835 1.03
 CCB + ACEI (n = 27) 143.1 ± 3.33 142.9 ± 3.46 −0.19 (−9.83 to 9.46) 0.969 0.13
DBP (mmHg)
DM only (n = 38) 74.87 ± 2.25 77.87 ± 1.80 3.00 (−2.75 to 8.74) 0.301 4.00
DM + HPT
 CCB (n = 11) 83.18 ± 3.74 83.55 ± 3.23 0.36 (−9.95 to 10.68) 0.942 0.43
 ARB (n = 22) 80.00 ± 2.31 80.02 ± 2.09 1.00 (−5.29 to 7.30) 0.750 1.25
 ACEI (n = 30) 80.01 ± 1.89 76.43 ± 2.37 −4.67 (−10.73 to 1.40) 0.128 5.76
 CAD (n = 8) 93.80 ± 5.23 104.4 ± 7.22 10.6 (−9.96 to 31.16) 0.086 11.30
 CCB + ARB (n = 24) 86.13 ± 3.33 86.08 ± 2.62 −0.04 (−8.58 to 8.50) 0.992 0.05
 CCB + ACEI (n = 27) 82.81 ± 2.78 84.41 ± 2.40 1.59 (−5.78 to 8.96) 0.666 1.92
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Overall, several of these biomarkers are higher than the 
recommended threshold for T2DM as suggested by the 
WHO and the ADA [35, 36]. For example, approximately 
60 and 69.2% of the participants were not able to achieve 
the desired FBG and HbA1c targets respectively. This is 
in fact disturbing given the direct association between 
abnormal plasma glucose levels and macrovascular or 
microvascular complications. Efforts to control glucose 
levels are necessary and could be achieved in several 
ways. After diagnosis, medical nutrition therapy (MNT) 
is necessary to reduce weight and normalise glucose lev-
els [37].
However, it has been established that MNT alone is not 
sufficient for improving plasma glucose levels. As such, 
the use of medications becomes the next phase of action 
[37].
In Ghana, several glucose lowering medications have 
been approved for the treatment of hyperglycaemia 
including SUAs, TNZs and biguanides, the latter being 
the first line anti-diabetic medicine [5]. Like many other 
countries, its popularity is because: (1) it is less expensive, 
(2) it is effective for weight reduction and plasma glucose 
levels, and (3) it has a reduced risk for hypoglycaemia 
[38]. Not surprisingly, a high proportion of our partici-
pants (>80%) were on this medication, most of whom 
had used this drug for a period long before the start of 
this study. However, the majority of those who used BIG 
(metformin) alone could not achieve the desired glycae-
mic level even at follow up although there seems to be a 
minimal percentage effect (29.6%, p = 0.0094) on HbA1c 
level (Tables 3, 4, 5). This emphasises the failure of met-
formin as a monotherapy to achieve glucose control. At 
this point, the focus shifts towards individuals undergo-
ing combination and multiple therapies.
SUAs and TNZs have been recognised as second line 
anti-diabetic medications and their efficacy is similar to 
metformin [25, 38]. However, it was apparent after six 
months that even with multiple therapies, the majority 
of the patients could not attain the desired glucose target 
levels. Only a minimal percentage effect of BIG +  SUA 
(19.2%, p =  0.0175) on HbA1c was observed (Table  5). 
Several reasons can be attributed to this:
Firstly, there is a possibility of poor adherence to oral 
medications, especially among those taking combina-
tion and multiple therapies, not only for hyperglycaemia 
but also for other comorbidities [26, 38, 39]. Moreover, 
many of these drugs are associated with side effects and 
hence it is possible that some participants will be selec-
tive in their choice of medicine (Additional file  1: Table 
S1). In a study among 2849 T2DM patients in the UK, it 
was shown that only 13% of the patients adhered strictly 
to the drug regimen [40]. This could possibly be the case 
in our study as some participants may have become bored 
with swallowing different medications daily. Efforts to 
simplify treatment regimens should therefore be intensi-
fied. For example, instead of multiple medications, single-
dose combination pills with minimal side effects could 
be administered. Secondly, ensuring adequate control of 
glycaemic status requires a paradigm shift from sedentary 
behaviour to a more physically active lifestyle. One study 
has shown that moderate-intensity physical activity such 
as brisk walking and reducing time spent watching tel-
evision to less than 30 min per day could reduce several 
modifiable T2DM risk factors including plasma LDL-c 
and TG while increasing HDL-c [41]. A meta-analysis also 
showed that physical activity is inversely associated with 
risk for T2DM [42].
Moreover, intense exercise is necessary to stimu-
late 5-adenosine monophosphate-activated kinase 
(5-AMPK) causing the release of glucose to the mus-
cles rather than it accumulating in the plasma [4]. In 
our study however, we were unable to assess the level or 
intensity of physical activity by the individuals. There-
fore, an effective physical assessment tool such as the 
international physical activity questionnaire (IPAQ) 
could be useful [43].
Thirdly, poor dietary preferences may have been a con-
tributory factor. Studies have shown that healthy diets or 
consumption of vegetables, low calorie diets, low trans 
fats, legumes, fruits, poultry, whole grains and cereal 
fibre is linked to a reduced risk of metabolic syndrome 
and T2DM [44, 45]. Conversely, consumption of red and 
processed meat, sugar-sweetened beverages, desserts and 
fried foods is associated with an increased risk of T2DM 
[44, 45]. However, whether or not the majority of the 
study participants utilised a particular food was unveri-
fied and therefore, a validated food frequency question-
naire would also have been useful.
Despite the increasing use of anti-hypertensives, BP 
control was suboptimal in our study population. With 
an attrition rate of nearly 40%, only 52 T2DM partici-
pants who took anti-hypertensive medications were able 
to maintain a target BP (both SBP and DBP) at follow up 
(Table 7). Majority were unable to achieve a desired tar-
get although they took more than one antihypertensive 
drug. This is disturbing given that high BP is by far the 
most critical risk factor for cardiovascular disease (CVD) 
and stroke [46]. Other studies that have explored the role 
of intensive BP control in preventing CVD have pro-
duced conflicting results. One study showed that a DBP 
of ≤80 mmHg could reduce the risk of CVD by 50% [47]. 
However, another study reported that SBP ≤120  mmHg 
was not associated with a reduced risk for CVD [48]. 
Notwithstanding this, our findings agree with several 
other studies that BP is poorly controlled among T2DM 
patients worldwide [49, 50].
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Statins are well-known lipid lowering medications and 
the common one used by participants in this study is ator-
vastatin. More than half of the participants taking atorvas-
tatin had good lipid profiles and this is consistent with the 
findings by Wong et al. [39]. Moreover, our study showed 
that there was a significant improvement in several lipid 
markers such as TG, LDL-c, HDL-c and VDL-c at follow 
up (Table 6). Whether atorvastatin interfered with glucose 
homeostasis is yet to be determined but our study confirms 
that atorvastatin is a potent drug for treating dyslipidaemia.
The present study does have some limitations. Firstly, 
because it was an observational longitudinal study, it was 
limited by confounding factors such as differences in dos-
age regimen. Dosage regimen refers to the modality of drug 
administration/doses per unit of time to reach a therapeutic 
objective. This comprises the time or frequency when the 
drug should be administered, the time between doses and 
the amount or unit dose of medicine to be administered at 
a specific time [51–53]. However, given the number of par-
ticipants, each with a different medication dosage at a point 
in time, it was difficult to take into consideration the dosage 
regimen. At the same time, certain tests especially FBG are 
influenced by biological variation even when fluoride tubes 
are used. For example, stressful situations in the hours pre-
ceding FBG test could increase FBG levels [54]. Thus, we 
were unable to provide a full explanation on the poor drug 
response among some participants. Secondly, a clinical ran-
domised control trial would have eliminated potential con-
founding factors, and also shed further light on the effect of 
the various medications in lowering modifiable risk factors. 
Thirdly, the sample size of the study was small and therefore 
cannot be representative of the entire T2DM population. 
Finally, over 40% of the participants were lost to follow up 
and this may have had an effect on our assessments.
Conclusion
Our study showed that the use of statins is effective for 
improving lipid profiles and can be regarded as a potent 
medication for treating dyslipidaemia. However, utilisa-
tion of oral hypoglycaemic agents whether as a mono-
therapy, combination or polytherapy was not effective for 
achieving plasma glucose targets of <7%. This is alarming 
and therefore, alternative approaches including a less sed-
entary lifestyle while engaging in vigorous exercise may 
reduce weight and obesity; enforcing healthy eating prac-
tices and administration of single/fixed-dose combina-
tion tablets or pills with minimal side effects may improve 
medication adherence (Additional file 1: Table S1).
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